Cargando…
Efficacy of a Treat-and-Extend Regimen With Ranibizumab in Patients With Neovascular Age-Related Macular Disease: A Randomized Clinical Trial
IMPORTANCE: Although the Canadian Treat-and-Extend Analysis Trial With Ranibizumab in Patients With Neovascular Age-Related Macular Disease (CANTREAT) reported herein and the Treat and Extend study provided data to show noninferiority of treat-and-extend (T&E) at 12 months, to date there are few...
Autores principales: | Kertes, Peter J., Galic, Ivan J., Greve, Mark, Williams, Geoff, Baker, Jason, Lahaie, Marcel, Sheidow, Tom |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Medical Association
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6990694/ https://www.ncbi.nlm.nih.gov/pubmed/31917441 http://dx.doi.org/10.1001/jamaophthalmol.2019.5540 |
Ejemplares similares
-
Ranibizumab in neovascular age-related macular degeneration
por: Eng, Kenneth T, et al.
Publicado: (2006) -
Safety and Efficacy of Different Doses and Regimens of Faricimab vs Ranibizumab in Neovascular Age-Related Macular Degeneration: The AVENUE Phase 2 Randomized Clinical Trial
por: Sahni, Jayashree, et al.
Publicado: (2020) -
Functional and anatomical outcome of eyes with neovascular age-related macular degeneration treated with intravitreal ranibizumab following an exit strategy regimen
por: Menke, Marcel N, et al.
Publicado: (2014) -
Ranibizumab 0.5 mg treat-and-extend regimen for diabetic macular oedema: the RETAIN study
por: Prünte, Christian, et al.
Publicado: (2016) -
Bevacizumab versus Ranibizumab on As-Needed Treatment Regimen for Neovascular Age-Related Macular Degeneration in Turkish Patients
por: Ozkaya, Abdullah, et al.
Publicado: (2013)